Stefanie Hagenow

Multitarget‐Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H₃R Antagonism for Neurodegenerative Diseases

Óscar M. Bautista‐Aguilera, Stefanie Hagenow, Alejandra Palomino‐Antolín et al. · Angewandte Chemie International Edition · 2017 · 100 citations

Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Aβ1-42 aggregation

Erika Plazas, Stefanie Hagenow, Mónica Constanza Ávila Murillo et al. · Bioorganic Chemistry · 2020 · 58 citations

Pharmaceutical Chemistry, Biochemistry, Zanthoxylum Rigidum +8

Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson’s disease

Anna Affini, Stefanie Hagenow, Aleksandra Živković et al. · European Journal of Medicinal Chemistry · 2018 · 51 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Functional Selectivity +8

Selenazolyl-hydrazones as Novel Selective MAO Inhibitors With Antiproliferative and Antioxidant Activities: Experimental and In-silico Studies

Hana Elshaflu, Tamara R. Todorović, Milan Nikolić et al. · Frontiers in Chemistry · 2018 · 44 citations · Full text

Search for new multi-target compounds against Alzheimer’s disease among histamine H3 receptor ligands

Marek Bajda, Dorota Łażewska, Justyna Godyń et al. · European Journal of Medicinal Chemistry · 2019 · 35 citations · Full text

Molecular Pharmacology, Neurodegenerative Diseases, Drug Target +8